NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)

Pavurutamab

NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Sponsor

Amgen

A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)

---

ClinicalTrials.gov Identifier: NCT04998747

Official Title: A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)

First Posted : August 10, 2021

Click here for details on ClinicalTrials.gov

---

pavurutamab - anti-BCMA/CD3 BiTE antibody AMG 701

AMG 701

Pavurutamab (Code C147028)

AMG 701

AMG-701

AMG701

Anti-BCMA x Anti-CD3 BiTE AMG 701

Anti-BCMA/CD3 BiTE Antibody AMG 701

BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701

Bispecific T-cell Engager Antibody AMG 701

BiTE Antibody AMG 701

Pavurutamab

PAVURUTAMAB

Drug: AMG 701

---

Locations